SK3 Group, Inc. (PINK: SKTO) Applied DNA Sciences, Inc. (OTC: APDN) Sigma Labs, Inc. (OTC: SGLB) and Advanced Cell Technology Inc. (OTC: ACTC) are stocks we have been keeping a close eye on in recent weeks.
SK3 Group, Inc. is a healthcare logistics and fulfillment consultancy focused on the delivery of alternative care and medicine. With seasoned management, breakthrough technology and best practices, the Company brings standardization and transparency to this rapidly growing segment of the alternative care field.
For our complete article on SKTO please go here: http://tinyurl.com/otcmagic-sk3
Applied DNA Sciences, Inc. (OTC: APDN is a provider of botanical-DNA based security and authentication solutions that can help protect products, brands and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion. SigNature(R) DNA and smartDNA(R), our principal anti-counterfeiting and product authentication solutions that essentially cannot be copied, provide a forensic chain of evidence and can be used to prosecute perpetrators.
For our complete article on APDN please go here: http://tinyurl.com/otcmagic-applied-dna
Sigma Labs is focused on serving the aerospace industry and has developed several important technologies including the revolutionary PrintRite3D technology which will allow metals parts to be made by 3D printing or additive manufacturing with fewer flaws and better properties. Another groundbreaking technology is a rapid healing biomedical implant technology that has already been proven for dental applications and is being investigated for orthopedics. Yet another critical technology is in the area of reactive munitions which provide 50% greater energy with less weight and lower collateral damage for current and future conflicts.
For our complete article on SGLB please go here: http://tinyurl.com/otcmagic-sigma-labs
Advanced Cell Technology, Inc., a biotechnology company, engages in the development and commercialization of human embryonic and adult stem cell technology in the field of regenerative medicine. The company is conducting various clinical trials for treating macular degeneration, and has a preclinical development pipeline focused on products for eye diseases, autoimmune and inflammatory diseases, and wound healing. Its intellectual property portfolio includes pluripotent stem cell platforms comprising embryonic stem cell and induced pluripotent stem cell (iPSC) platforms; and other cell therapy research programs, such as opthamology, autoimmune/inflammation, and platelet programs.
For our complete article on ACTC please go here: http://tinyurl.com/otcmagic-advanced-actc
OTCMAGIC is a newsletter that reports on developments in the world of penny stocks. OTCMagic is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit OTCMagic.com website, for complete risks and disclosures.
Subscribe Here: http://www.otcmagic.com/
Leave a comment...